多巴胺受体激动剂在延缓和治疗帕金森病相关运动并发症中的临床应用(5)
Bracco F, Battaglia A, Chouza C, et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson’s disease: final results of a 5-year, double-blind, levodopa-controlled study [J]. CNS Drugs, 2004, 18(11): 733-746.Battistin L, Bardin PG, Ferro-Milone F, et al. Alpha-dihydroergocryptine in Parkinson’s disease: a multicentre randomized double blind parallel group study [J]. Acta Neurol Scand ......
您现在查看是摘要页,全文长 3493 字符。